{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:21:46Z","timestamp":1777418506117,"version":"3.51.4"},"reference-count":50,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[1995,6,1]],"date-time":"1995-06-01T00:00:00Z","timestamp":801964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[1995,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To provide a comprehensive review of the pharmacokinetic and pharmacodynamic interactions between antipsychotics and antihypertensives and to provide recommendations for the selection of antihypertensives in patients receiving antipsychotic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A MEDLINE search of the English-language literature was used to identify pertinent human and animal studies, reviews, and case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection:<\/jats:title>\n                    <jats:p>All available sources were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Extraction:<\/jats:title>\n                    <jats:p>Background information was obtained from comprehensive reviews. Individual case reports were assimilated, and pertinent data were extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Because hypertension is common in patients with psychiatric illness and antihypertensive agents are used for a multiplicity of indications, significant numbers of patients receive concurrent therapy with antihypertensives and antipsychotics. Many antipsychotics may block the antihypertensive efficacy of guanethidine and related drugs. The interaction between Clonidine and antipsychotics is defined less clearly. Limited data suggest possible additive hypotensive effects when chlorpromazine and methyldopa are given in combination. Increased plasma concentrations of thioridazine with a resultant increase in adverse effects have been reported when propranolol or pindolol are added to the regimen. A similar increase in chlorpromazine concentrations has been reported when propranolol was added. Although there are no reports documenting an interaction between a calcium-channel antagonist and an antipsychotic, the possible inhibition of oxidative metabolism of antipsychotics, additive calcium-blocking activity, and additive pharmacodynamic effects are theorized. Hypotension and postural syncope were reported in a patient given therapeutic dosages of chlorpromazine and Captopril, and in 2 patients when clozapine was added to enalapril therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>No antipsychotic-antihypertensive combination is absolutely contraindicated, but no combination should be considered to be completely without risk. Antihypertensives with no centrally acting activity, such as diuretics, may be the least likely to result in adverse reactions. The combination of the beta-antagonists propranolol or pindolol with thioridazine or chlorpromazine should be avoided if possible. Scrupulous patient monitoring for attenuated or enhanced activity of either agent is essential whenever antipsychotics and antihypertensives are given concurrently.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/106002809502900610","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T10:24:44Z","timestamp":1484303084000},"page":"603-609","source":"Crossref","is-referenced-by-count":42,"title":["Interactions Between Antipsychotic and Antihypertensive Drugs"],"prefix":"10.1177","volume":"29","author":[{"given":"John S","family":"Markowitz","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy Practice and Administration, Medical University of South Carolina"}]},{"given":"Barbara G","family":"Wells","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, Samford University"}]},{"given":"William H","family":"Carson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina"}]}],"member":"179","published-online":{"date-parts":[[1995,6,1]]},"reference":[{"key":"bibr1-106002809502900610","doi-asserted-by":"crossref","unstructured":"Joint National Committee. The fifth report of the joint national committee on detection evaluation and treatment of high blood pressure. Arch Intern Med 1993;153:154-83.","DOI":"10.1001\/archinte.153.2.154"},{"key":"bibr2-106002809502900610","doi-asserted-by":"crossref","unstructured":"HonigA, PopP, deKemp E, PhilipsenH, RommeMA. Physical illness in chronic psychiatric patients from a community psychiatric unit revisited. Br J Psychiatry 1992;161:80-3.","DOI":"10.1192\/bjp.161.1.80"},{"key":"bibr3-106002809502900610","doi-asserted-by":"crossref","unstructured":"BarnesRF, MasonJC, GreerC, RayFT. Medical illness in chronic psychiatric outpatients. Gen Hosp Psychiatry 1983;5:191-5.","DOI":"10.1016\/0163-8343(83)90055-5"},{"key":"bibr4-106002809502900610","doi-asserted-by":"crossref","unstructured":"CottingtonEM, BrockBM, HouseJS. Psychosocial factors and blood pressure in the Michigan statewide blood pressure survey. Am J Epidemiol 1985;121:515-28.","DOI":"10.1093\/oxfordjournals.aje.a114029"},{"key":"bibr5-106002809502900610","doi-asserted-by":"crossref","unstructured":"WheatelyD, BaiterM, LevineJ, LipmanR, BauerML, BaratoR. Psychiatric aspects of hypertension. Br J Psychiatry 1975;127:327-36.","DOI":"10.1192\/bjp.127.4.327"},{"key":"bibr6-106002809502900610","unstructured":"PerryPJ, AlexanderB, LiskowBI. Psychotropic drug handbook. 6th ed. Cincinnati: Harvey Whitney Books, 1991:114-5, 142\u20133, 195-6."},{"key":"bibr7-106002809502900610","unstructured":"LeibowitzMR, SchneierF, CampeasR, GormanJ, FyerA, HollanderE, Phenelzine and atenolol in social phobia. Psychopharmacol Bull 1990;26:123-5."},{"key":"bibr8-106002809502900610","unstructured":"WellsBG. Verapamil in the treatment of schizophrenia. Ann Pharmacother 1990;24:838-40."},{"key":"bibr9-106002809502900610","unstructured":"KaplanHI, SadockBJ. Synopsis of psychiatry. Baltimore: Williams and Wilkins, 1988:254."},{"key":"bibr10-106002809502900610","doi-asserted-by":"crossref","unstructured":"McCarrickAK, ManderscheidRW, BertolucciDE, GoldmanH, TesslerRC. Chronic medical problems in the chronically mentally ill. Hosp Commun Psychiatry 1986;37:289-91.","DOI":"10.1176\/ps.37.3.289"},{"key":"bibr11-106002809502900610","doi-asserted-by":"crossref","unstructured":"RichelsonE, NelsonOA. Antagonism of neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984;103:197-204.","DOI":"10.1016\/0014-2999(84)90478-3"},{"key":"bibr12-106002809502900610","doi-asserted-by":"crossref","unstructured":"SnyderSH, ReynoldsIJ. Drugs, neurotransmitters and schizophrenia. Science 1974;184:1243-53.","DOI":"10.1126\/science.184.4143.1243"},{"key":"bibr13-106002809502900610","doi-asserted-by":"crossref","unstructured":"RaghebM. Drug interactions in psychiatric practice. Int Pharmacopsychiatry 1981;16:92-118.","DOI":"10.1159\/000468482"},{"key":"bibr14-106002809502900610","unstructured":"RisenSC, GroomGP, JanowskyDS. Interfaces of psychopharmacology and cardiology\u2013-part one. J Clin Psychiatry 1981;42:23-4."},{"key":"bibr15-106002809502900610","doi-asserted-by":"crossref","unstructured":"GreendykeRM, KanterDR. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. J Clin Psychopharmacol 1987;7:178-82.","DOI":"10.1097\/00004714-198706000-00013"},{"key":"bibr16-106002809502900610","doi-asserted-by":"crossref","unstructured":"SilverJM, YudofskySC, KoganM. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry 1986;143:1290-2.","DOI":"10.1176\/ajp.143.10.1290"},{"key":"bibr17-106002809502900610","doi-asserted-by":"crossref","unstructured":"LindstromLH, PersonE. Propranolol in chronic schizophrenia: a controlled study in neuroleptic-treated patients. Br J Psychiatry 1980;137:126-30.","DOI":"10.1192\/bjp.137.2.126"},{"key":"bibr18-106002809502900610","doi-asserted-by":"crossref","unstructured":"PeetM, MiddlemissDN, YatesRA. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients (letter). Lancet 1980;2:978.","DOI":"10.1016\/S0140-6736(80)92135-2"},{"key":"bibr19-106002809502900610","doi-asserted-by":"crossref","unstructured":"MillerFA, RamplingD. Adverse effects of combined propranolol and chlorpromazine therapy. Am J Psychiatry 1982;139:1189-99.","DOI":"10.1176\/ajp.139.9.1198"},{"key":"bibr20-106002809502900610","doi-asserted-by":"crossref","unstructured":"VestalRE, KornhauserDM, HollifieldJW. Inhibition of propranolol metabolism by chlorpromazine. Clin Pharmacol Ther 1979;25:19-24.","DOI":"10.1002\/cpt197925119"},{"key":"bibr21-106002809502900610","doi-asserted-by":"crossref","unstructured":"AlexanderHE McCartyK, GiffenM. Hypotension and cardiopulmonary arrest associated with concurrent haloperidol and propranolol therapy. JAMA 1984;252:87-8.","DOI":"10.1001\/jama.252.1.87"},{"key":"bibr22-106002809502900610","unstructured":"GreendykeRM, GuylaA. Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin and phenobarbital. J Clin Psychiatry 1988;49:105-7."},{"key":"bibr23-106002809502900610","first-page":"791","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Gerber JG","year":"1990","edition":"8"},{"key":"bibr24-106002809502900610","doi-asserted-by":"crossref","unstructured":"BriantRH, DiamondBI. Interaction between Clonidine and desipramine in man. Br Med J 1973;852:522-3.","DOI":"10.1136\/bmj.1.5852.522"},{"key":"bibr25-106002809502900610","doi-asserted-by":"crossref","unstructured":"Van ZwietenPA. Interactions interfering with central adrenoceptor activity and hypotension of centrally acting antihypertensive agents. Prog Brain Res 1977;47:385-90.","DOI":"10.1016\/S0079-6123(08)62741-7"},{"key":"bibr26-106002809502900610","doi-asserted-by":"crossref","unstructured":"Van ZwietenPA. Reduction of the hypotensive effect of clonidine and alpha-methyldopa by various psychotropic drugs. Clin Sci 1976;51(suppl):411s-3s.","DOI":"10.1042\/cs051411s"},{"key":"bibr27-106002809502900610","doi-asserted-by":"crossref","unstructured":"Van ZwietenPA. The interaction between clonidine and the various neuroleptic agents and some benzodiazepine tranquilizers. J Pharm Pharmacol 1976;29:229-34.","DOI":"10.1111\/j.2042-7158.1977.tb11294.x"},{"key":"bibr28-106002809502900610","doi-asserted-by":"crossref","unstructured":"PetersonEN. Pre- and postsynaptic alpha-adrenoceptor antagonism by neuroleptics in vivo. Eur J Pharmacol 1981;69:399-405.","DOI":"10.1016\/0014-2999(81)90443-X"},{"key":"bibr29-106002809502900610","doi-asserted-by":"crossref","unstructured":"FruncilloRJ, GibbonsWJ, VlassesPH, FergusonRK. Severe hypotension associated with concurrent clonidine and antipsychotic medication (letter). Am J Psychiatry 1985;142:274.","DOI":"10.1176\/ajp.142.2.274a"},{"key":"bibr30-106002809502900610","unstructured":"AllenRM, FlemenbaumA. Delirium associated with combined fluphenazine-clonidine therapy. J Clin Psychiatry 1979;40:236-7."},{"key":"bibr31-106002809502900610","unstructured":"ChouinardG, PinardG, PrenoveauY, TetreaultL. Alpha-methyldopa-chlorpromazine interaction in schizophrenia patients. Curr Ther Res 1973;15:60-71."},{"key":"bibr32-106002809502900610","unstructured":"ChouinardG, PinardG, SerranoM, TetreaultL. Potentiation of haloperidol by alpha-methyldopa in the treatment of schizophrenia. Curr Ther Res 1973;15:473-83."},{"key":"bibr33-106002809502900610","unstructured":"RankinGO, WatkinsBE, SawutzDG. Chlorpromazine interactions with guanethidine and alpha-methyldopa. Effects on arterial pressure control and heart rate in renovascular hypertensive rats. Arch Int Pharmacodyn Ther 1982;260:130-40."},{"key":"bibr34-106002809502900610","doi-asserted-by":"crossref","unstructured":"ThorntonWE. Dementia induced by methyldopa with haloperidol. N Engl J Med 1976:294:1222.","DOI":"10.1056\/NEJM197605272942208"},{"key":"bibr35-106002809502900610","doi-asserted-by":"crossref","unstructured":"NadelI, WallachM. Drug interaction between haloperidol and methyldopa (letter). Br J Psychiatry 1979:135:484.","DOI":"10.1192\/bjp.135.5.484b"},{"key":"bibr36-106002809502900610","doi-asserted-by":"crossref","unstructured":"WhiteWB. Hypertension with postural syncope secondary to the combination of chlorpromazine and captopril. Arch Intern Med 1986;146:1833-4.","DOI":"10.1001\/archinte.146.9.1833"},{"key":"bibr37-106002809502900610","doi-asserted-by":"crossref","unstructured":"AronowitzJS, ChakosMH, SaffermanAZ, LiebermanJA. Syncope associated with the combination of clozapine and enalapril. J Clin Psychopharmacol 1994;14:429-30.","DOI":"10.1097\/00004714-199412000-00013"},{"key":"bibr38-106002809502900610","doi-asserted-by":"crossref","unstructured":"SnyderSH, ReynoldsIJ. Calcium-antagonist drugs. Receptor interactions that clarify therapeutic effects. N Engl J Med 1985;313:995-1002.","DOI":"10.1056\/NEJM198510173131606"},{"key":"bibr39-106002809502900610","doi-asserted-by":"crossref","unstructured":"PollackMH, RosenbaumJF, HymanSE. Calcium channel blockers in psychiatry. Psychosomatics 1987;28:356-69.","DOI":"10.1016\/S0033-3182(87)72509-2"},{"key":"bibr40-106002809502900610","doi-asserted-by":"crossref","unstructured":"HuntBA, SelfTH, LalondeRL. Calcium channel blockers as inhibitors of drug metabolism. Chest 1989;96:393-9.","DOI":"10.1378\/chest.96.2.393"},{"key":"bibr41-106002809502900610","doi-asserted-by":"crossref","unstructured":"KirchW, KleinblosemCH, BeizGG. Drug interactions with calcium antagonists. Pharmacol Ther 1990;45:109-36.","DOI":"10.1016\/0163-7258(90)90011-P"},{"key":"bibr42-106002809502900610","doi-asserted-by":"crossref","unstructured":"Fonne-PfisterR, MeyerUA. Xenobiotic and endobiotic inhibitors of cytochrome P450 dbl function, the target of the debrisoquine\/sparteine type polymorphism. Biochem Pharmacol 1988;37:3829-35.","DOI":"10.1016\/0006-2952(88)90063-9"},{"key":"bibr43-106002809502900610","doi-asserted-by":"crossref","unstructured":"CholertonS, DalyAK, IdleJR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992;13:434-9.","DOI":"10.1016\/0165-6147(92)90140-2"},{"key":"bibr44-106002809502900610","doi-asserted-by":"crossref","unstructured":"HuangM, Van PeerA, WoestenborghR, De CosterR, HeykantsJ, JansenA, Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.","DOI":"10.1038\/clpt.1993.146"},{"key":"bibr45-106002809502900610","unstructured":"SmithPJ, TalbertRL. Sexual dysfunction with antihypertensive and antipsychotic agents. Clin Pharm 1986;5:373-84."},{"key":"bibr46-106002809502900610","doi-asserted-by":"crossref","unstructured":"MitchellJR, AriasL, OatesJA. Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA 1967;202:973-6.","DOI":"10.1001\/jama.202.10.973"},{"key":"bibr47-106002809502900610","doi-asserted-by":"crossref","unstructured":"JanowskyDS, El-YousefMK, DavisJM. Antagonism of guanethidine by chlorpromazine. Am J Psychiatry 1973;130:808-12.","DOI":"10.1176\/ajp.130.7.808"},{"key":"bibr48-106002809502900610","doi-asserted-by":"crossref","unstructured":"GilderDA, FainW, SimpsonLL. A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine. Pharmacol Exp Ther 1976;198:255-63.","DOI":"10.1016\/S0022-3565(25)30592-6"},{"key":"bibr49-106002809502900610","doi-asserted-by":"crossref","unstructured":"SimpsonLL. Combined use of molindone and guanethidine in patients with schizophrenia and hypertension. Am J Psychiatry 1979;136:1410-4.","DOI":"10.1176\/ajp.136.11.1410"},{"key":"bibr50-106002809502900610","doi-asserted-by":"crossref","unstructured":"ThorntonWE, PrayBJ. Ventricular arrhythmia and thioridazine: a case report. Am J Nurs 1976;76:245-6.","DOI":"10.1097\/00000446-197602000-00035"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809502900610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809502900610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:20Z","timestamp":1777374440000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/106002809502900610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,6]]}},"alternative-id":["10.1177\/106002809502900610"],"URL":"https:\/\/doi.org\/10.1177\/106002809502900610","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,6]]}}}